Vetmedin 1.25 mg Flavoured Chewable Tablets for Dogs

País: Nova Zelanda

Idioma: anglès

Font: Ministry for Primary Industries

ingredients actius:

pimobendan; pimobendan

Disponible des:

Boehringer Ingelheim Animal Health New Zealand Limited

Composición:

pimobendan 100 g/kg; pimobendan 62.5 g/kg

Área terapéutica:

Cardiovascular agent

Estat d'Autorització:

ACVM Registered

Data d'autorització:

2018-05-01

Fitxa tècnica

Product: Vetmedin 1.25 mg Flavoured Chewable Tablets for Dogs
Date: 05 Feb 2021
ACVM No.: A011511
Page 1 of 6
Page 1 of 6
Blister Pack
FOR ANIMAL TREATMENT ONLY
VETMEDIN
® 1.25 MG FLAVOURED CHEWABLE TABLETS FOR DOGS
EACH TABLET CONTAINS 1.25 MG PIMOBENDAN
Boehringer Ingelheim Animal Health Australia Pty. Ltd.
78 Waterloo Road
North Ryde NSW 2113
Phone: [phone]
NEW ZEALAND INFO
RVM
ACVM No. A011511
Boehringer Ingelheim Animal Health New Zealand Ltd.
Freephone: 0800 800 822
Batch No.:
Expiry Date:
Product: Vetmedin 1.25 mg Flavoured Chewable Tablets for Dogs
Date: 05 Feb 2021
ACVM No.: A011511
Page 2 of 6
Page 2 of 6
Folding Box Label
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
VETMEDIN
® 1.25 MG
FLAVOURED CHEWABLE TABLETS FOR DOGS
EACH TABLET CONTAINS 1.25 MG PIMOBENDAN
50 TABLETS
Vetmedin
® Flavoured Chewable Tablets for Dogs are indicated for:
The treatment of canine congestive heart failure (CHF) originating
from dilated
cardiomyopathy (DCM) or valvular insufficiency (mitral and/or
tricuspid regurgitation).
The treatment of preclinical DCM in large breed dogs. When used in
cases of preclinical DCM
in large breed dogs, pimobendan significantly prolonged the time to
the onset of CHF or
sudden death, and also resulted in prolongation of the time to death
due to all causes.
Doberman Pinscher dogs with preclinical DCM treated with pimobendan
also demonstrated a
significant reduction in Left Ventricular Internal Diameter in both
systole and diastole
(LVIDs/d) in response to therapy.
For the treatment of dogs with evidence of increased heart size
secondary to asymptomatic
(preclinical) myxomatous mitral valve disease to delay the onset of
clinical symptoms of heart
failure, to reduce heart size and to increase survival time.
READ THE ENCLOSED LEAFLET FOR FULL INSTRUCTIONS
DIRECTIONS FOR USE
DOSAGE AND ADMINISTRATION
Vetmedin
®
Chewable Tablets should be administered orally at a dose range of 0.1
– 0.3 mg
pimobendan/kg bodyweight twice daily. The ideal dose is 0.25 mg
p